Zydus Lifesciences gets USFDA nod for prostate cancer drug Enzalutamide
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg (USRLD: Xtandi Capsules, 40 mg).
Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body, such as the bones or lymph nodes, and continues to progress despite hormone therapies that lower testosterone levels. Patients often experience symptoms like bone pain, fatigue, and weight loss. mCRPC is generally aggressive, with varying prognoses depending on individual health and response to treatment, necessitating a multidisciplinary approach for effective management.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.